#AANAM – Givlaari Reduces Pain, Lowers Pain Killer Use in AHP
Six months of treatment with Givlaari (givosiran) effectively reduced pain during and between porphyria attacks in people with acute hepatic porphyria (AHP), also known as acute porphyria, according to a post-hoc analysis of data from the Phase 3 ENVISION trial. Givlaari also was found to lower the use of…